<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract The COVID-19 pandemic is due to" exact="infection" post="caused by the novel SARS-CoV-2 virus that impacts the"/>
 <result pre="different strains may help correlate COVID-19-related severity, mortality rate, and" exact="treatment" post="options. For example, using a phylogenetic network analysis approach"/>
 <result pre="Direct RNA sequencing (without requiring reverse transcription) has further allowed" exact="detection" post="of RNA modifications on the genomic RNA (Table 1)."/>
 <result pre="may further explain the gastrointestinal symptoms associated with the viral" exact="infection" post="as well as its detection in faeces [50]. In"/>
 <result pre="symptoms associated with the viral infection as well as its" exact="detection" post="in faeces [50]. In a recent study, it has"/>
 <result pre="cell [46] (Figure 1a). The current knowledge of the cellular" exact="infection" post="pathway involving ACE2 and TMPRSS2 thus provide good candidates"/>
 <result pre="spread rapidly, there is a growing demand for rapid point-of-care" exact="testing" post="of the virus. The current gold standard for diagnosing"/>
 <result pre="virus. The current gold standard for diagnosing COVID-19 depends upon" exact="detection" post="of the viral genetic material (RNA) in a nasopharyngeal"/>
 <result pre="can detect the virus earlier in the infection, it requires" exact="polymerase chain reaction" post="(PCR), a technology that amplifies the amount of genetic"/>
 <result pre="Although the antibody associated tests are faster, their use for" exact="diagnosis" post="is limited by the fact that it usually takes"/>
 <result pre="takes several days and up to two weeks after an" exact="infection" post="takes place for antibodies to be detectable. Therefore, antibody-based"/>
 <result pre="infection takes place for antibodies to be detectable. Therefore, antibody-based" exact="testing" post="is not a reliable method to diagnose COVID-19; however,"/>
 <result pre="to diagnose COVID-19; however, they may be useful for population-based" exact="testing" post="to estimate the proportion of the population with immunity"/>
 <result pre="and social segregation of susceptible individuals. A third type of" exact="testing" post="relies on detecting viral proteins (antigens) likely to be"/>
 <result pre="it for future protection. Furthermore, such a vaccine can prevent" exact="infection" post="since it would inhibit virus entry into susceptible cells."/>
 <result pre="acid in special 80 nm ionizable, glycol-lipid nanoparticles and clinical" exact="testing" post="is expected commence shortly [59]. Another vaccine that has"/>
 <result pre="other novel vaccine approaches and therapeutic interventions to combat viral" exact="infection" post="[57,59,60]. For example, Inovio Pharmaceuticalsâ€™ INO-4800 (Plymouth Meeting, PA,"/>
 <result pre="over the last two decades against SARS, MERS, and H1N1" exact="infection" post="[61,62,63]. In this therapy, plasma (with neutralizing antibodies) is"/>
 <result pre="these can be used to develop functional antibodies as a" exact="treatment" post="for COVID-19 [59,66]. For example, AbCellera, a Canadian biotech"/>
 <result pre="Enzyme 2 (ACE2) ACE2 is the host receptor for SARS-CoV-2" exact="infection" post="that interacts with the viral spike protein to gain"/>
 <result pre="hindering this interaction could potentially be used as an effective" exact="treatment" post="in COVID-19 patients [67]. Consistent with this hypothesis, a"/>
 <result pre="they go on to show that hrsACE2 could inhibit virus" exact="infection" post="of human engineered blood vessel and kidney organoids. These"/>
 <result pre="new window of opportunity to use hrsACE2 to prevent SARS-CoV-2" exact="infection" post="at a very early stage by blocking its entry"/>
 <result pre="Drug Repurposing for COVID-19 Given the need to find effective" exact="treatment" post="for symptomatic patients, the approach of repurposing old drugs"/>
 <result pre="The roles of existing antiretroviral drugs and pathways in COVID-19" exact="treatment" post="are as follows: Lopinavir (LPV)-Ritonavir (RTV) combination (Kaletra): This"/>
 <result pre="against both SARS and MERS indicate its potential for COVID-19" exact="treatment" post="[69,70,71,72]. Lopinavir-Ritonavir has been used either on its own"/>
 <result pre="either alpha interferon (China) or chloroquine/hydroxychloroquine (South Korea) for COVID-19" exact="treatment" post="with some success [73,74]. However, new data from China"/>
 <result pre="clinical trials are needed to establish the efficacy of this" exact="treatment" post="for COVID-19 which are currently underway. Favipiravir (Favilavir or"/>
 <result pre="the effects of FPV versus LPV/RTV were compared during the" exact="treatment" post="of COVID-19 patients. The FPV-treated patients demonstrated much better"/>
 <result pre="country [66]. Chloroquine/Hydroxychloroquine: Chloroquine is an inexpensive drug for the" exact="treatment" post="of malaria and features on the WHO list of"/>
 <result pre="It is also used as an anti-inflammatory agent for the" exact="treatment" post="of autoimmune diseases. Chloroquine is thought to inhibit virus"/>
 <result pre="pneumonia and acceptable safety margin with use of chloroquine for" exact="treatment" post="of COVID-19 [10]. Hydroxychloroquine is an analogue of chloroquine"/>
 <result pre="before conclusive recommendations can be made for chloroquine/hydroxychloroquine in the" exact="treatment" post="of COVID-19. Interestingly, chloroquine and hydroxychloroquine are zinc ionophores"/>
 <result pre="it has been used as an investigational drug for the" exact="treatment" post="of Ebola, MERS-CoV, and SARS-CoV2, and other RNA viruses,"/>
 <result pre="for numerical reduction in time to clinical improvement [95]. Furthermore," exact="treatment" post="with remdesivir had to be stopped early in some"/>
 <result pre="showed favorable changes of CT findings within 14 days of" exact="treatment" post="[100]. It is turning out to be a promising"/>
 <result pre="This strongly suggests that PAK1-inhibitors could be valuable for the" exact="treatment" post="of COVID-19 infection. PAK-1 inhibitors include caffeic acid and"/>
 <result pre="interventions (NPI) such as early case identification and isolation, vigilant" exact="contact tracing" post="of potential secondary cases, travel restrictions and bans, stringent"/>
 <result pre="(NPI) such as early case identification and isolation, vigilant contact" exact="tracing" post="of potential secondary cases, travel restrictions and bans, stringent"/>
 <result pre="Inc., a Canadian AI company for infectious diseases, flagged unusual" exact="infection" post="related activity in Wuhan, China and reported the spread"/>
 <result pre="February 12-March 16, 2020Morb. Mortal. Wkly. Rep. (MMWR)20206934334610.15585/mmwr.mm6912e232214079 9.LiR.PeiS.ChenB.SongY.ZhangT.YangW.ShamanJ.Substantial undocumented" exact="infection" post="facilitates the rapid dissemination of novel coronavirus (SARS-CoV2)Science202036848949310.1126/science.abb322132179701 10.GaoJ.TianZ.YangX.Breakthrough:"/>
 <result pre="coronavirus (SARS-CoV2)Science202036848949310.1126/science.abb322132179701 10.GaoJ.TianZ.YangX.Breakthrough: Chloroquine phosphate has shown apparent efficacy in" exact="treatment" post="of COVID-19 associated pneumonia in clinical studiesBiosci. Trends202014727310.5582/bst.2020.0104732074550 11.AndersenK.G.RambautA.LipkinW.I.HolmesE.C.GarryR.F.The"/>
 <result pre="(2019-nCoV/SARS-CoV-2) receptor ACE2 in different populationsCell Discov.202061410.1038/s41421-020-0147-131934347 52.WangY.KangH.LiuX.TongZ.Combination of RT-qPCR" exact="testing" post="and clinical features for diagnosis of COVID-19 facilitates management"/>
 <result pre="populationsCell Discov.202061410.1038/s41421-020-0147-131934347 52.WangY.KangH.LiuX.TongZ.Combination of RT-qPCR testing and clinical features for" exact="diagnosis" post="of COVID-19 facilitates management of SARS-CoV-2 outbreakJ. Med. Virol.20209253853910.1002/jmv.25721"/>
 <result pre="Hong KongEur. J. Clin. Microbiol. Infect. Dis.200524444610.1007/s10096-004-1271-915616839 62.HungI.F.ToK.K.LeeC.K.LeeK.L.ChanK.YanW.W.LiuR.WattC.L.ChanW.M.LaiK.Y.et al.Convalescent plasma" exact="treatment" post="reduced mortality in patients with severe pandemic influenza A"/>
 <result pre="studyHong Kong Med. J.2003939940614660806 72.ChuC.M.ChengV.C.HungI.F.WongM.M.ChanK.H.ChanK.S.KaoR.Y.PoonL.L.WongC.L.GuanY.et al.Role of lopinavir/ritonavir in the" exact="treatment" post="of SARS: Initial virological and clinical findingsThorax20045925225610.1136/thorax.2003.01265814985565 73.LimJ.JeonS.ShinH.Y.KimM.J.SeongY.M.LeeW.J.ChoeK.W.KangY.M.LeeB.ParkS.J.Case of"/>
 <result pre="74.YanD.LiuX.ZhuY.HuangL.DanB.ZhangG.GaoY.Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir" exact="treatment" post="in patients with SARS-CoV-2 infectionMedRxiv202010.1101/2020.03.22 75.CaoB.WangY.WenD.LiuW.WangJ.FanG.RuanL.SongB.CaiY.WeiM.et al.A Trial of"/>
 <result pre="Open-Label Control StudyEngineering2020in press10.1016/j.eng.2020.03.007 79.AkpovwaH.Chloroquine could be used for the" exact="treatment" post="of filoviral infections and other viral infections that emerge"/>
 <result pre="Ebola virus replication in vitro but failed to protect against" exact="infection" post="and disease in the in vivo guinea pig modelJ."/>
 <result pre="(2019-nCoV) in vitroCell Res.20203026927110.1038/s41422-020-0282-032020029 84.GautretP.LagierJ.C.ParolaP.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.DupontH.T.et al.Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: Results of an open-label non-randomized clinical trialInt."/>
 <result pre="Pneumo-, and ParamyxovirusesSci. Rep.201774339510.1038/srep4339528262699 92.de WitE.FeldmannF.CroninJ.JordanR.OkumuraA.ThomasT.ScottD.CihlarT.FeldmannH.Prophylactic and therapeutic remdesivir (GS-5734)" exact="treatment" post="in the rhesus macaque model of MERS-CoV infectionProc. Natl."/>
 <result pre="of CT findings in a patient with COVID-19 pneumonia after" exact="treatment" post="with tocilizumabDiagn. Interv. Imag.2020in press10.1016/j.diii.2020.03.010 101.PascuaP.N.LeeJ.H.SongM.S.ParkS.J.BaekY.H.AnnB.H.ShinE.Y.KimE.G.ChoiY.K.Role of the p21-activated"/>
 <result pre="and its interaction with its host cellular receptor, ACE2. The" exact="infection" post="pathway is shown where after docking of the virus"/>
</results>
